Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Cagrilintide
Max Weight Loss0%
Studies8
Participants1,847
StatusLimited

Cagrilintide

Long-Acting Amylin Receptor Agonist

Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.

Complete Research Database

Dual Receptor Mechanism (GIP/GLP-1)

GLP-1 Receptor Pathway

  • •Increases insulin secretion (glucose-dependent)
  • •Suppresses glucagon release
  • •Slows gastric emptying
  • •Enhances satiety in hypothalamus
  • •Preserves beta-cell function

GIP Receptor Pathway

  • •Enhances insulin secretion (stronger than GLP-1)
  • •Promotes fat oxidation
  • •Improves insulin sensitivity in muscle
  • •Reduces hepatic glucose production
  • •Modulates adipose tissue metabolism

Why Dual Agonism is Superior

Cagrilintide is a long-acting amylin receptor agonist that activates amylin receptors in the brain and gastrointestinal tract. Amylin is naturally co-secreted with insulin from pancreatic beta cells and plays a crucial role in appetite regulation and glucose homeostasis. By activating amylin receptors in the area postrema and nucleus tractus solitarius of the brainstem, cagrilintide provides potent appetite suppression. It also slows gastric emptying, reduces glucagon secretion, and enhances insulin sensitivity, complementing GLP-1 pathway activation.

Pharmacokinetic Profile

~5 days
Half-life
8-72 hours
Tmax
80%
Bioavailability
99%
Protein binding
Proteolytic cleavage
Metabolism
Renal (primary)
Elimination

Top 10 High-Quality Research Articles

Once-weekly cagrilintide for weight management in people with overweight and obesity

Read
The Lancet (2021)
N = 706
High Impact
10.8% weight reduction with 4.5mg dose over 26 weeks
DOI: 10.1016/S0140-6736(21)02640-4

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with semaglutide

Read
The Lancet (2023)
N = 92
High Impact
15.6% weight reduction with CagriSema combination over 32 weeks
DOI: 10.1016/S0140-6736(23)01163-7

Amylin as a Future Obesity Treatment

Read
Frontiers in Endocrinology (2021)
N = 0
Medium Impact
Review of amylin pathway mechanisms and therapeutic potential
DOI: 10.3389/fendo.2021.758477

Efficacy and safety of cagrilintide alone and in combination with semaglutide: Meta-analysis

Read
Indian Journal of Endocrinology and Metabolism (2024)
N = 798
Medium Impact
Meta-analysis confirms superior efficacy of combination therapy
DOI: 10.4103/ijem.ijem_143_24

Cagrilintide Combined with Semaglutide: New Approach for Obesity Treatment

Read
Current Drug Targets (2024)
N = 350
Medium Impact
Synergistic weight loss effects through dual pathway activation
DOI: 10.2174/1389450125666240112153045
Want more research? Search PubMed for 'cagrilintide' - over 45 peer-reviewed articles available on amylin receptor agonism and weight management.

Medical Disclaimer

This information is for educational purposes only. Cagrilintide is currently in Phase 3 clinical trials and is not yet approved for commercial use. It requires prescription and medical supervision when available. This content does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Participation in clinical trials may be available through clinicaltrials.gov.